Although the direct regulation of FOXM1 by LXRα was validated in hepatocellular carcinoma and macrophages [29, 52], our study validated this regulation in PCa and provided a novel therapeutic strategy for targeting the FOXM1 pathway and PCS1 subtype. This evidence concerns the gene FOXM1 and posterior cortical atrophy.